IUPAC/Chemical Name
(2R,3S,4aR,12bS)-2,3,4a,8-tetrahydroxy-12b-(((5R,6R)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-3-methyl-3,4,4a,12b-tetrahydrotetraphene-1,7,12(2H)-trione
InChi Key
CKZNKYSWWCSICZ-ZDPMPSPESA-N
InChi Code
InChI=1S/C25H26O10/c1-11-14(26)6-7-16(34-11)35-25-18-13(19(28)17-12(20(18)29)4-3-5-15(17)27)8-9-24(25,33)10-23(2,32)21(30)22(25)31/h3-5,8-9,11,14,16,21,26-27,30,32-33H,6-7,10H2,1-2H3/t11-,14-,16?,21+,23+,24+,25-/m1/s1
SMILES Code
O=C1[C@H](O)[C@@](C)(O)C[C@]2(O)[C@@]1(OC3CC[C@@H](O)[C@@H](C)O3)C4=C(C(C5=C(C4=O)C=CC=C5O)=O)C=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
486.47
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Take Y, Sawada M, Kunai H, Inouye Y, Nakamura S. Role of the naphthoquinone moiety in the biological activities of sakyomicin A. J Antibiot (Tokyo). 1986 Apr;39(4):557-63. PubMed PMID: 2423491.
2: Tanaka N, Okabe T, Tanaka N, Take Y, Inouye Y, Nakamura S, Nakashima H, Yamamoto N. Inhibition by sakyomicin A of avian myeloblastosis virus reverse transcriptase and proliferation of AIDS-associated virus (HTLV-III/LAV). Jpn J Cancer Res. 1986 Apr;77(4):324-6. PubMed PMID: 2422146.
3: Inouye Y, Okada H, Uno J, Arai T, Nakamura S. Effects of streptonigrin derivatives and sakyomicin A on the respiration of isolated rat liver mitochondria. J Antibiot (Tokyo). 1986 Apr;39(4):550-6. PubMed PMID: 2872195.
4: Nagasawa T, Fukao H, Irie H, Yamada H. Sakyomicins A, B, C and D: new quinone-type antibiotics produced by a strain of Nocardia. Taxonomy, production, isolation and biological properties. J Antibiot (Tokyo). 1984 Jul;37(7):693-9. PubMed PMID: 6547943.
5: Inouye Y, Oogose K, Take Y, Kubo T, Nakamura S. Role of single-electron reduction potential in inhibition of reverse transcriptase by streptonigrin and sakyomicin A. J Antibiot (Tokyo). 1987 May;40(5):702-5. PubMed PMID: 2440841.
6: Take Y, Inouye Y, Nakamura S, Allaudeen HS, Kubo A. Comparative studies of the inhibitory properties of antibiotics on human immunodeficiency virus and avian myeloblastosis virus reverse transcriptases and cellular DNA polymerases. J Antibiot (Tokyo). 1989 Jan;42(1):107-15. PubMed PMID: 2466028.
7: Hafuri Y, Takemori E, Oogose K, Inouye Y, Nakamura S, Kitahara Y, Nakahara S, Kubo A. Mechanism of inhibition of reverse transcriptase by quinone antibiotics. II. Dependence on putative quinone pocket on the enzyme molecule. J Antibiot (Tokyo). 1988 Oct;41(10):1471-8. PubMed PMID: 2461354.
